COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA

  • Safina Shabbir Pakistan Naval Ship (PNS) Shifa Hospital, Karachi/National University of Medical Sciences (NUMS) Pakistan
  • Zill -e- Humayun Pakistan Naval Ship (PNS) Shifa Hospital, Karachi/National University of Medical Sciences (NUMS) Pakistan
  • Muhammad Javad Yousaf Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Muhammad Adnan Manzar Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Shabana Mushtaq Pakistan Naval Ship (PNS) Shifa Hospital, Karachi/National University of Medical Sciences (NUMS) Pakistan
  • Maria Yousaf Pakistan Naval Ship (PNS) Shifa Hospital, Karachi/National University of Medical Sciences (NUMS) Pakistan
Keywords: Atorvastatin, Diabetes mellitus, Hyperlipidemia, Rosuvastatin

Abstract

Objective: To evaluate & compare the mean change in fasting serum total cholesterol and LDL-C levels from baseline, after 12 weeks of oral treatment with oral Rosuvastatin and with Atorvastatin in type 2 diabetic patients with primary hyperlipidemia.

Study Design: Cross sectional comparative study.

Place and Duration of Study: The present study was conducted in the Medicine Department, Pakistan Naval Ship, Shifa Hospital, Karachi, from Mar to Sep 2016.

Methodology: The sample was collected by non- probability convenient sampling. The total of 114 DM type 2 patients were randomly divided into two equal groups. Group A was given Rosuvastatin whereas group B was given Atorvastatin orally daily for 12 weeks along with oral treatment for diabetes. After 12 weeks, Fasting Serum Total Cholesterol and Serum LDL-C were estimated, and noted as final levels.

Results: There was greater reduction in terms of mean change in serum total cholesterol levels and low-density lipoprotein – cholesterol (LDL-C) levels with Rosuvastatin as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia.

Conclusion: Rosuvastatin can significantly improve lipid profile as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia.

Downloads

Download data is not yet available.
Published
2020-12-15
How to Cite
Shabbir, S., Humayun, Z., Yousaf, M., Manzar, M., Mushtaq, S., & Yousaf, M. (2020). COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA. PAFMJ, 70(6), 1671-75. Retrieved from https://pafmj.org/index.php/PAFMJ/article/view/5866
Section
Original Articles

Most read articles by the same author(s)